FP6Индивидуална стипендия2006–2007

AMEC · Artificial Metalloenzymes for Enantioselective Catalysis

6РП — Действия „Мария Кюри“

Период
2006-01-01 → 2007-10-31
Финансиране от ЕС
271 763 €
Участници
2
Схема
OIF

Линиите свързват координатора с партньорите. За проекти отпреди 2014 г. CORDIS не винаги дава точни координати. Тези точки са на ниво град или държава.

Накратко на български

Изкуствените металоензими се създават чрез поставяне на метални катализатори в протеинови кухини за синтезиране на чисти химически съединения. Това помага за по-ефективното производство на лекарства и биологично активни вещества.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Final Activity Report Summary - AMEC (Artificial metalloenzymes for enantioselective catalysis)

The preparation of enantiomerically pure compounds is one of the most intensively explored areas in organic synthetic chemistry. The field is of great importance for academic research, for the development of new drugs and materials, and, enantioenriched substances are being used in many industrial syntheses of pharmaceutical products and other biologically active substances. In the past three decades, metal-catalysed enantioselective transformations have attained a significant level of expertise and refinement as it was recognised that these are among the most efficient ways to produce enantioenriched materials. This effort was rewarded by the 2001 Nobel Prize in Chemistry, which was shared by Knowles, Noyori, and Sharpless. Nevertheless, despite significant advances, it remains very difficult to predict the outcome of a metal-catalysed asymmetric reaction and, as a consequence, the number of efficient catalysts used for industrial applications remains low. To circumvent the difficulty of predicting the enantioselectivity, combinatorial methodologies have successfully been applied to the discovery and to the elaboration of new chiral catalysts. These studies have shed light on the fact that many subtle experimental parameters often have a significant and unpredictable impact on the outcome of an asymmetric reaction. In recent years, enzymatic catalysis has emerged as an important alternative tool for the synthesis of enantiopure compounds. Again, despite widespread academic and industrial research efforts, the number of industrial biocatalyst applications remains limited. From these considerations, it appears that homogeneous and enzymatic catalyses are in many respects complementary. By grafting well-defined homogeneous catalysts inside a protein cavity, it is expected to create artificial metalloenzymes having properties reminiscent of both fields. The AMEC project aimed at designing homogeneous catalysts that could function either as traditional homogeneous catalysts or as enzymatic catalysts once grafted inside a protein cavity. During the outgoing period in Harvard University (Massachusetts, United States) the researcher developed chiral homobimetallic and heterobimetallic catalysts. The performance of these bioinspired catalysts is reminiscent of natural enzymes, both in terms of selectivity and in terms of activity.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Homogeneous and enzymatic catalyses are in many respects complementary. By anchoring an organometallic catalyst precursor into a host protein, we hoped to create artificial metalloenzymes with properties reminiscent of both areas. To be able to readily deconvolute the influence of the organometallic fragment from the influence of the protein, we want to focus on enantioselective catalysis. Incorporation of an achiral catalyst precursor in the host protein ensures that any level of enantioselection is induce d by the second coordination sphere provided by the protein. Such an approach offers several appealing features: (i) the possibility of dissociating the activity (primarily dictated by the organometallic catalyst precursor) from the selectivity (governed b y the host protein); (ii) the use of orthogonal diversity-generating procedures (molecular biology for the protein optimization as well as parallel synthesis for the organometallic fragment); and (iii) a novel approach to exploit weak interactions in enantioselective homogeneous catalysis. The approach we focus on relies on a non-covalent incorporation (i.e., supramolecular) of the organometallic catalyst precursor in the protein. Since no chemical coupling step is required upon addition of the catalyst precursor to the protein, we reasoned that the integrity of the organometallic species would be warranted. To ensure the localization of the organometallic catalyst precursor within the protein, however, a very strong non-covalent host-guest (i.e., a protein inhibitor) system should be selected.""

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз